Correction: Structure and inhibition of mouse leukotriene C4 synthase (PLoS ONE (2014) 9, 5 (e96763) DOI: 10.1371/journal.pone.0096763);Structure and inhibition of mouse leukotriene C4 synthase

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Niegowski, Damian ^a   Kleinschmidt, Thea ^a   Ahmad, Shabbir ^a   Qureshi, Abdul Aziz ^a,b   Mårback, Michaela ^a   Rinaldo Matthis, Agnes ^a   Haeggström, Jesper Z ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; LEUKOTRIENE C4 SYNTHASE; S HEXYLGLUTATHIONE; ENZYME INHIBITOR; GLUTATHIONE TRANSFERASE; ISOENZYME; LEUKOTRIENE-C4 SYNTHASE;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG RESEARCH; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME KINETICS; ENZYME STRUCTURE; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SPECIES COMPARISON; STEADY STATE; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; PROTEIN CONFORMATION;

AMINO ACID SEQUENCE; ANIMALS; BIOCATALYSIS; CLONING, MOLECULAR; ENZYME INHIBITORS; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION;

EID: 84901008812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099747     Document Type: Erratum

References (38)

1. Haeggstrom JZ, Funk CD (2011) Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 111: 5866-5898.
2. Samuelsson B (2012) Role of basic science in the development of new medicines: examples from the eicosanoid field. J Biol Chem 287: 10070-10080.
3. Peters-Golden M, Henderson WRJ (2007) Leukotrienes. N Engl J Med 357: 1841-1854.
4. Drazen JM, Israel E, O'Byrne PM (1999) Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 340: 197-206. (Pubitemid 29063217)
5. Heise CE, O'Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, et al. (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275: 30531-30536.
6. Lynch KR, O'Neill GP, Liu Q, Im DS, Sawyer N, et al. (1999) Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 789-793. (Pubitemid 29293175)
7. Bisgaard H (2001) Leukotriene modifiers in pediatric asthma management. Pediatrics 107: 381-390.
8. Haeggstrom JZ, Rinaldo-Matthis A, Wheelock CE, Wetterholm A (2010) Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun 396: 135-139.
9. Bresell A, Weinander R, Lundqvist G, Raza H, Shimoji M, et al. (2005) Bioinformatic and enzymatic characterization of the MAPEG superfamily. FEBS J 272: 1688-1703. (Pubitemid 40516219)
10. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B (1999) Common structural features of MAPEG - a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism. Protein Sci 8: 689-692. (Pubitemid 29117984)
11. Jegerschöld C, Pawelzik SC, Purhonen P, Bhakat P, Gheorghe KR, et al. (2008) Structural basis for induced formation of the inflammatory mediator prostaglandin E2. Proc Natl Acad Sci U S A 105: 11110-11115.
12. Ahmad S, Niegowski D, Wetterholm A, Haeggstrom JZ, Morgenstern R, et al. (2013) Catalytic characterization of human microsomal glutathione S-transferase 2: identification of rate-limiting steps. Biochemistry 52: 1755-1764.
13. Jakobsson PJ, Morgenstern R, Mancini J, Ford-Hutchinson A, Persson B (2000) Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily. Am J Respir Crit Care Med 161: S20-24. (Pubitemid 30129410)
14. Rinaldo-Matthis A, Wetterholm A, Molina DM, Holm J, Niegowski D, et al. (2010) Arginine 104 is a key catalytic residue in leukotriene C4 synthase. J Biol Chem 285: 40771-40776.
15. Martinez Molina D, Wetterholm A, Kohl A, McCarthy AA, Niegowski D, et al. (2007) Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 448: 613-616. (Pubitemid 47208483)
16. Niegowski D, Kleinschmidt T, Olsson U, Ahmad S, Rinaldo-Matthis A, et al. (2014) Crystal structures of Leukotriene C4 synthase in complex with product analogs, implications for the enzyme mechanism. J Biol Chem. 289: 5199-5207.
17. Lam BK, Penrose JF, Rokach J, Xu K, Baldasaro MH, et al. (1996) Molecular cloning, expression and characterization of mouse leukotriene C4 synthase. Eur J Biochem 238: 606-612. (Pubitemid 26235098)
18. Pawelzik SC, Uda NR, Spahiu L, Jegerschold C, Stenberg P, et al. (2010) Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1. J Biol Chem 285: 29254-29261.
19. Nilsson P, Pelcman B., Katkevics M. (2013) Bis aromatic compounds for use as LTC4 synthase inhibitors. Internat Publication Nr WO/2011/110824.
20. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67: 235-242.
21. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132.
22. Karplus PA, Diederichs K (2012) Linking crystallographic model and data quality. Science 336: 1030-1033.
23. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674. (Pubitemid 47080256)
24. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255. (Pubitemid 27235885)
25. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
26. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132. (Pubitemid 41742764)
27. DeLano WL (2002) The PyMOL Molecular Graphics System In: scientific D, editor. Palo Alto.
28. Ago H, Kanaoka Y, Irikura D, Lam BK, Shimamura T, et al. (2007) Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448: 609-612. (Pubitemid 47206929)
29. Rinaldo-Matthis A, Ahmad S, Wetterholm A, Lachmann P, Morgenstern R, et al. (2012) Pre-steady-state kinetic characterization of thiolate anion formation in human leukotriene C synthase. Biochemistry 51: 848-856.
30. Ago H, Kanaoka Y, Irikura D, Lam BK, Shimamura T, et al. (2007) Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis. Nature 448: 609-U612.
31. Molina DM, Wetterholm A, Kohl A, McCarthy AA, Niegowski D, et al. (2007) Structural basis for synthesis of inflammatory mediators by human leukotriene C-4 synthase. Nature 448: 613-U613.
32. Saino H, Ukita Y, Ago H, Irikura D, Nisawa A, et al. (2011) The Catalytic Architecture of Leukotriene C(4) Synthase with Two Arginine Residues. J Biol Chem. 286: 16392-16401.
33. Svartz J, Blomgran R, Hammarstrom S, Soderstrom M (2003) Leukotriene C4 synthase homo-oligomers detected in living cells by bioluminescence resonance energy transfer. Biochim Biophys Acta 1633: 90-95. (Pubitemid 36851634)
34. Ago H, Okimoto N, Kanaoka Y, Morimoto G, Ukita Y, et al. (2013) A leukotriene C4 synthase inhibitor with the backbone of 5-(5-methylene-4-oxo-4,5- dihydrothiazol-2-ylamino) isophthalic acid. J Biochem 153: 421-429.
35. Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, et al. (2007) Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 317: 510-512. (Pubitemid 47196114)
36. Di Gennaro A, Wagsater D, Mayranpaa MI, Gabrielsen A, Swedenborg J, et al. (2010) Increased expression of leukotriene C4 synthase and predominant formation of cysteinyl-leukotrienes in human abdominal aortic aneurysm. Proc Natl Acad Sci U S A 107: 21093-21097.
37. Funk CD (2005) Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov 4: 664-672.
38. Brunger AT (1993) Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Crystallogr D Biol Crystallogr 49: 24-36.